Breaking News
18 hours ago
Simantini Singh Deo

Novo Nordisk's ziltivekimab misses its Phase III cardiovascular endpoint, intensifying pressure to diversify beyond obesity.
Simantini Singh Deo

AstraZeneca and Bristol Myers Squibb reportedly held preliminary merger talks for a combined company worth almost $400 billion.
Simantini Singh Deo

Novo Nordisk's ziltivekimab fails to significantly reduce cardiovascular risk in a Phase III trial, sending shares down 7.3%.
Simantini Singh Deo

Ascentage Pharma names Dr. Faiçal Miyara as CBO and Jim Ziegler as CCO to drive its global business development and commercial expansion.
Simantini Singh Deo
